Gavin M. Wright, MBBS, FRACS, PhD

Gavin Wright, MBBS, explains what the phase 3 VISUALIZE 2 trial aims to confirm about abenacianine's surgical benefit for patients with lung cancer.

Gavin Wright, MBBS, discusses how the tumor-targeted imaging agent abenacianine helped surgeons locate hard-to-find tumors in the phase 2b VISUALIZE trial.

The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.